Epidermal growth factor receptor tyrosine kinase inhibitors

Clinical trials of selective small-molecule inhibitors of epidermal growth factor receptor tyrosine kinase activity have shown that these targeted inhibitors of proliferative signal transduction provide well-tolerated antitumour activity in patients. Preclinical pharmacology studies illustrate the p...

Full description

Saved in:
Bibliographic Details
Published in:Current Opinion in Pharmacology 2002-08, Vol.2 (4), p.382-387
Main Author: Wakeling, Alan E
Format: Article
Language:English
Subjects:
Animals
chemoprevention
Drug Therapy, Combination
Enzyme Inhibitors - chemistry
Enzyme Inhibitors - therapeutic use
Epidermal growth factor receptor tyrosine kinase inhibitor
Humans
Iressa
Neoplasms - drug therapy
Neoplasms - enzymology
Protein-Tyrosine Kinases - antagonists & inhibitors
Protein-Tyrosine Kinases - metabolism
Quinazolines - chemistry
Quinazolines - therapeutic use
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - metabolism
ZD1839
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical trials of selective small-molecule inhibitors of epidermal growth factor receptor tyrosine kinase activity have shown that these targeted inhibitors of proliferative signal transduction provide well-tolerated antitumour activity in patients. Preclinical pharmacology studies illustrate the potential use of these new cancer therapeutics in combination with chemotherapy, radiotherapy and hormone therapy, and in chemoprevention, in a spectrum of solid human tumours. Small-molecule inhibitors of epidermal growth factor receptor tyrosine kinase, like Iressa, may be the first in a new wave of well-tolerated, orally administered signal transduction inhibitor drugs with activity against common solid tumours.
ISSN:1471-4892
1471-4973
DOI:10.1016/S1471-4892(02)00183-2